

REMARKS

Claims 1-15, 17-18 and 22-24 are pending in the present application.

Claims 7, 15 and 17-18 have been amended to better recite the subject matter therein. Such amendments have not been made in view of the prior art. In view the foregoing amendments and remarks, Applicants respectfully request reconsideration, a withdrawal of all rejections and a Notice of Allowability.

Claim 7 has been objected to since it does not end in a period. Applicants have amended Claim 7 to address this objection. Claims 15 and 17-18 are also objected to as being of improper dependent form. The Office alleges that these claims do not further limit the compounds of Claim 1. Applicants have redrafted these claims in independent form, and therefore this objection is now believed to be moot. The Office also objects to the term "other therapeutic ingredients" as being unclear since it is undefined. Applicants disagree and respectfully submit that such a term is well-known in the art as referring to active ingredients with therapeutic effect. Non-limiting examples of such therapeutic ingredients are provided on Applicants' published PCT specification pn page 16, line 10 through page 21, line 6.

Claim 15 is rejected under 35 U.S.C. § 112, first paragraph, for lack of enablement. The Office admits that this claim is enabled for treating asthma, depression, congestive heart failure, etc. The Office alleges, however, that this claim is not enabled for the prophylaxis of any of them. Although Applicants do not agree with the position of the Office, the term "prophylaxis" has been deleted to expedite prosecution. Moreover, in conjunction with the treatment of asthma, the National Institute of Health indicates that long-term control medicines may be taken every day, usually over long periods of time, to prevent symptoms and asthma episodes or attacks. See eg.,

http://www.nhlbi.nih.gov/health/dci/Diseases/Asthma/Asthma_Treatments.html

A withdrawal of this rejection is therefore respectfully solicited.

The points of the Office Action being addressed in full, a Notice of Allowance is respectfully solicited.

Respectfully submitted,

/Robert J. Smith/
Robert J. Smith
Attorney for Applicant
Registration No. 40,820

Date: June 12, 2008
GlaxoSmithKline/Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-9616
Facsimile: 919-483-7988